oxybutynin has been researched along with Osteoarthritis in 10 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
Osteoarthritis: A progressive, degenerative joint disease, the most common form of arthritis, especially in older persons. The disease is thought to result not from the aging process but from biochemical changes and biomechanical stresses affecting articular cartilage. In the foreign literature it is often called osteoarthrosis deformans.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Efficacy and tolerability of buprenorphine patches was demonstrated in chronic pain patients, regardless of age, supporting the conclusion that no age-related dose adjustment of transdermal buprenorphine is needed." | 7.80 | Is buprenorphine transdermal patch equally safe and effective in younger and elderly patients with osteoarthritis-related pain? Results of an age-group controlled study. ( Augustini, BG; Berggren, AC; Karlsson, J; Söderström, A, 2014) |
| " The majority of drug-related adverse events (AEs) included mild dermatitis at the application sites and occurred in 46." | 6.82 | The Long-Term Safety of S-Flurbiprofen Plaster for Osteoarthritis Patients: An Open-Label, 52-Week Study. ( Hoshino, Y; Matsumoto, H; Matsushita, I; Otsuka, N; Yataba, I, 2016) |
| "Adult patients with pain from osteoarthritis receiving a stable dosage of HCD/APAP (i." | 6.77 | A randomized, 14-day, double-blind study evaluating conversion from hydrocodone/acetaminophen (Vicodin) to buprenorphine transdermal system 10 μg/h or 20 μg/h in patients with osteoarthritis pain. ( Landau, CJ; McCarberg, BH; Munera, C; Ripa, SR; Wen, W, 2012) |
| "Efficacy and tolerability of buprenorphine patches was demonstrated in chronic pain patients, regardless of age, supporting the conclusion that no age-related dose adjustment of transdermal buprenorphine is needed." | 3.80 | Is buprenorphine transdermal patch equally safe and effective in younger and elderly patients with osteoarthritis-related pain? Results of an age-group controlled study. ( Augustini, BG; Berggren, AC; Karlsson, J; Söderström, A, 2014) |
| " The majority of drug-related adverse events (AEs) included mild dermatitis at the application sites and occurred in 46." | 2.82 | The Long-Term Safety of S-Flurbiprofen Plaster for Osteoarthritis Patients: An Open-Label, 52-Week Study. ( Hoshino, Y; Matsumoto, H; Matsushita, I; Otsuka, N; Yataba, I, 2016) |
| "Adult patients with pain from osteoarthritis receiving a stable dosage of HCD/APAP (i." | 2.77 | A randomized, 14-day, double-blind study evaluating conversion from hydrocodone/acetaminophen (Vicodin) to buprenorphine transdermal system 10 μg/h or 20 μg/h in patients with osteoarthritis pain. ( Landau, CJ; McCarberg, BH; Munera, C; Ripa, SR; Wen, W, 2012) |
| " The primary outcomes were pain relief for RCTs and risk of adverse effects (AEs) for observational studies." | 2.58 | Relative efficacy and safety of topical non-steroidal anti-inflammatory drugs for osteoarthritis: a systematic review and network meta-analysis of randomised controlled trials and observational studies. ( Doherty, M; Lei, G; Li, J; Li, X; Long, H; Persson, MSM; Sarmanova, A; Wang, Y; Wei, J; Xie, D; Zeng, C; Zhang, W, 2018) |
| "This syndrome is usually related to anatomic variants (involving the bone structures, fibrous bands, or muscles and tendons)." | 1.38 | Supraclavicular nerve entrapment syndrome. ( Bruyère, PJ; Courtois, AC; Crielaard, JM; Douchamps, F, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (90.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Härkänen, L | 1 |
| Hakomäki, H | 1 |
| Huopio, J | 1 |
| Kokki, H | 1 |
| Korhonen, S | 1 |
| Lehtonen, M | 1 |
| Sjövall, S | 1 |
| Kokki, M | 1 |
| Zeng, C | 1 |
| Wei, J | 1 |
| Persson, MSM | 1 |
| Sarmanova, A | 1 |
| Doherty, M | 1 |
| Xie, D | 1 |
| Wang, Y | 1 |
| Li, X | 1 |
| Li, J | 1 |
| Long, H | 1 |
| Lei, G | 1 |
| Zhang, W | 1 |
| Feragalli, B | 1 |
| Dugall, M | 1 |
| Luzzi, R | 1 |
| Ledda, A | 1 |
| Hosoi, M | 1 |
| Belcaro, G | 1 |
| Cesarone, MR | 1 |
| Ban, T | 1 |
| Hirose, H | 1 |
| Teraura, H | 1 |
| Kotani, K | 1 |
| Gotoh, T | 1 |
| Therkleson, T | 1 |
| Karlsson, J | 1 |
| Söderström, A | 1 |
| Augustini, BG | 1 |
| Berggren, AC | 1 |
| Yataba, I | 1 |
| Otsuka, N | 1 |
| Matsushita, I | 1 |
| Matsumoto, H | 1 |
| Hoshino, Y | 1 |
| Argoff, CE | 1 |
| Douchamps, F | 1 |
| Courtois, AC | 1 |
| Bruyère, PJ | 1 |
| Crielaard, JM | 1 |
| Ripa, SR | 1 |
| McCarberg, BH | 1 |
| Munera, C | 1 |
| Wen, W | 1 |
| Landau, CJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT01276431] | Phase 4 | 102 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| A Randomized, Double-Blind Study Evaluating the Dose Conversion From Vicodin® to Buprenorphine Transdermal System (BTDS) in Subjects With Osteoarthritis (OA) Pain[NCT00312572] | Phase 3 | 204 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The indicator variable was 1 = completion, and 0 = noncompletion. For the primary efficacy analysis, the percentage of subjects who completed the double-blind phase was computed with its 95% confidence interval (CI) for each treatment regimen (starting dose of BTDS 10 or BTDS 20) across and within baseline Vicodin® stratum (15 to 22.5mg/day vs >22.5 to 30 mg/day as determined by the daily average hydrocodone dose during the run-in period). (NCT00312572)
Timeframe: 14 days
| Intervention | Percentage of Participants (Number) | ||
|---|---|---|---|
| 15 - 22.5 mg HCD (Stratum 1) | more than 22.5 - 30 mg HCD (Stratum 2) | Overall | |
| Combined Total | 85 | 82 | 84 |
| Double-blind BTDS 10/20 | 88 | 85 | 87 |
| Double-blind BTDS 20 | 83 | 79 | 82 |
2 reviews available for oxybutynin and Osteoarthritis
| Article | Year |
|---|---|
Relative efficacy and safety of topical non-steroidal anti-inflammatory drugs for osteoarthritis: a systematic review and network meta-analysis of randomised controlled trials and observational studies.
Topics: Administration, Cutaneous; Anti-Inflammatory Agents, Non-Steroidal; Bayes Theorem; Humans; Network M | 2018 |
Recent developments in the treatment of osteoarthritis with NSAIDs.
Topics: Administration, Oral; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Humans; Osteoarthritis; S | 2011 |
2 trials available for oxybutynin and Osteoarthritis
| Article | Year |
|---|---|
The Long-Term Safety of S-Flurbiprofen Plaster for Osteoarthritis Patients: An Open-Label, 52-Week Study.
Topics: Administration, Topical; Aged; Anti-Inflammatory Agents, Non-Steroidal; Dermatitis, Contact; Female; | 2016 |
A randomized, 14-day, double-blind study evaluating conversion from hydrocodone/acetaminophen (Vicodin) to buprenorphine transdermal system 10 μg/h or 20 μg/h in patients with osteoarthritis pain.
Topics: Acetaminophen; Administration, Cutaneous; Administration, Oral; Aged; Analgesics, Opioid; Anti-Infla | 2012 |
6 other studies available for oxybutynin and Osteoarthritis
| Article | Year |
|---|---|
Buprenorphine plasma and cerebrospinal fluid concentrations in osteoarthritis patients during low-dose transdermal patch dosing.
Topics: Administration, Cutaneous; Analgesics, Opioid; Buprenorphine; Humans; Osteoarthritis; Transdermal Pa | 2023 |
Pycnogenol®: supplementary management of symptomatic osteoarthritis with a patch. An observational registry study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Female; Flavonoids; Humans; Inflammation; Knee; Male | 2019 |
Multiple physician visits after restricting the prescription of compresses/patches in a Japanese rural community: preliminary results.
Topics: Administration, Topical; Aged; Aged, 80 and over; Female; Humans; Male; Office Visits; Osteoarthriti | 2019 |
Topical Ginger Treatment With a Compress or Patch for Osteoarthritis Symptoms.
Topics: Administration, Topical; Aged; Female; Humans; Male; Middle Aged; New Zealand; Osteoarthritis; Pain; | 2014 |
Is buprenorphine transdermal patch equally safe and effective in younger and elderly patients with osteoarthritis-related pain? Results of an age-group controlled study.
Topics: Age Factors; Aged; Aged, 80 and over; Analgesics, Opioid; Buprenorphine; Chronic Pain; Female; Human | 2014 |
Supraclavicular nerve entrapment syndrome.
Topics: Analgesics; Antirheumatic Agents; Brachial Plexus; Clavicle; Humans; Lidocaine; Male; Middle Aged; N | 2012 |